Lincoln Park 4-bedroom duplex with Juliet balconies: $2.1M
Listed: June 23, 2025
Price: $2,095,000
Listing agent: Cadey O'Leary, @properties, 773-710-4202
This four-bedroom duplex in a brick and limestone building has a side entrance with a foyer entry and 3½ bathrooms. The front living and dining room is framed by three east-facing, floor-to-ceiling sliding doors with Juliet balconies and a gas fireplace with custom built-ins. The home has natural white oak flooring, crown molding, 9½-foot ceilings and oversize windows. The kitchen has an 8-foot island, a separate dining area, quartzite countertops, Sub-Zero and Wolf appliances, including dual dishwashers, and a butler's pantry with a built-in beverage station. The family room, anchored by a second fireplace, opens to a covered terrace, one of three outdoor spaces outfitted with porcelain pavers and gas, water and electric service. The primary suite has a walk-in closet, a reading nook and a bath with a steam shower, soaking tub, heated floors, dual vanities and a water closet. Outdoor amenities include a two-car garage, a garage roof deck and a snowmelt system for walkways and stairs.
Some listing photos are 'virtually staged,' meaning they have been digitally altered to represent different furnishing or decorating options.
To feature your luxury listing of $1,000,000 or more in Chicago Tribune's Dream Homes, send listing information and high-res photos to ctc-realestate@chicagotribune.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Politics and Trade Collide as Trump Upends African Ties
Welcome to Next Africa, a twice-weekly newsletter on where the continent stands now — and where it's headed. Sign up here to have it delivered to your email. President Cyril Ramaphosa is scrambling to contain the fallout from the 30% tariffs the US has imposed on South African imports, the highest levied on goods from any sub-Saharan African nation.
Business Wire
3 hours ago
- Business Wire
Covita Health Partners Launches with a Mission to Make Expert Life Sciences Consulting More Accessible and Impactful
DENVER--(BUSINESS WIRE)-- Covita Health Partners, a newly launched regulatory and quality consulting firm, is proud to announce its entry into the life sciences industry by offering expert, affordable support to innovators developing medical devices, diagnostics, digital health technologies, combination products, human tissue-based therapies, and more. With a focus on accessibility, creativity, and measurable value, Covita is redefining what it means to be a consulting partner in today's dynamic healthcare environment. 'We started Covita because we saw talented teams and groundbreaking innovations stalling, not for lack of vision, but for lack of the right guidance at the right time." Founded to Fill a Critical Gap Covita Health Partners was founded in response to a growing and urgent need in the market. Life science innovators, especially early-stage teams, are being asked to do more with fewer resources, yet access to experienced, practical regulatory and quality support remains limited. Without that support, promising products face costly delays, missed opportunities, and in many cases, never reach the patients who need them most. 'In this industry, timing and execution are everything,' said Jeff Dupont, Chief Executive Officer and Co-Founder of Covita Health Partners. 'We started Covita because we saw talented teams and groundbreaking innovations stalling, not for lack of vision, but for lack of the right guidance at the right time.' The stakes are high: 75% of medical device startups fail, and the statistics are not much better in other segments of the life sciences. Covita Health Partners is committed to changing that. By providing smart, flexible support, and crafting creative, resource-conscious strategies, Covita helps innovators overcome early obstacles, accelerate development, and stay on a clear path to market. Industries Served and Services Offered Covita Health Partners supports clients across the life sciences spectrum, including: Medical Devices In Vitro Diagnostics (IVDs) Digital Health & AI-enabled technologies Combination Products Human Tissue-Based Products Reproductive Medicine Wellness Products and Supplements Its service offerings span the entire product lifecycle, some of which are listed below: Regulatory strategy and submissions (e.g., 510(k), De Novo, PMA, Q-Sub, CE marking, MDL) Quality management systems and ISO 13485 readiness Design control and risk management Software lifecycle and cybersecurity compliance Supplier qualification and management Audit readiness and inspection support (including PAI and ISO audits) Postmarket surveillance, complaint handling, and change control A True Partner, Not Just a Service Provider Unlike traditional consultants that offer one-size-fits-all services, Covita takes a tailored, hands-on approach. Its team engages as a true partner and scales support to match the client's stage and structure, and provides mentorship, training, and flexible solutions that grow with the organization. 'We're not just here to tick boxes,' said Dupont. 'We're here to solve problems creatively, teach as we go, and make sure our clients understand not only what they need to do, but why. That's how you build long-term success and foster long-term relationships.' Delivering Real, Measurable Value Covita's approach is designed to drive impact where it matters most. Clients benefit from: Faster time to market through proactive planning and targeted execution Reduced risk by staying ahead of regulatory requirements Smarter spending through right-sized systems and support Stronger investor confidence thanks to clear, executable strategies Empowered teams with increased internal capability and confidence Accessible Expertise for a Healthier Future Whether preparing for your first FDA submission, entering the EU market, or scaling operations after securing funding, Covita Health Partners brings clarity, experience, and creativity to the table, without the inflated cost or inflexibility of traditional firms. 'At Covita, we believe innovation shouldn't be held back by access to regulatory and quality support,' said Dupont. 'Our mission is to close that gap, so innovative medical products can reach the patients who need them.'
Yahoo
3 hours ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine
ST. PAUL, Minn., Aug. 5, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and children's hospital in Qatar, has been awarded a $100,000 G-Rex® Grant. Sidra Medicine's G-Rex® Grant will enable expeditious development, validation, and implementation of a G-Rex® centric CAR-T cell production platform. The G-Rex Grant will allow Sidra Medicine to perform the processes and preclinical development for a CD19 CAR-T cell therapy product that will initially be used in pediatric oncology settings. Sidra Medicine will also receive early access to the G-CART™ process currently in development at Cell Ready, the world's first and only G-Rex centric contract development and manufacturing organization (CDMO). The Grant will also support the implementation of fully closed system, semi-automated G-Rex production compliant with current Good Manufacturing Practices (cGMPs). Lastly, the Grant will support the technology transfer to Sidra Medicine's newly established GMP facility for qualification and implementation. "Sidra Medicine is a pioneering healthcare institution that has innovation weaved into the very core of its precision medicine program. Our GMP facility has been specifically set up to develop better treatment protocols for pediatric diseases including cancers, genetic and rare diseases. The G-Rex® Grant will play a key role in accelerating the readiness of our protocols, particularly for Sidra Medicine's pediatric oncology program. Our preliminary findings have already shown us that the G-Rex® method is outstanding in its simplicity and the unique T cell phenotype resulting from the cell culture. This methodology will allow us to implement an affordable, highly efficient G-Rex based cell manufacturing platform with the most suitable T cell phenotype, ultimately having a positive impact on pediatric patient care and cure," said Sara Deola, M.D., Ph.D., Research Investigator at Sidra Medicine. "We're eager to support the emerging Cell & Gene Therapy (CGT) industry in Qatar and the Middle East. By entering the field of CAR-T without any preconceived manufacturing notions and quickly gathering and reviewing G-Rex manufacturing data, Sidra Medicine quickly recognized the full array of advantages that our G-Rex centric manufacturing process offers relative to alternatives. Sidra Medicine's quick grasp of the technical and economic advantages of G-Rex relative to alternatives gives us confidence that this grant will set the stage for low cost and fully scalable CAR-T manufacturing in Qatar and the Middle East." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. ScaleReady's G-Rex Grant Program has now surpassed $40M of no-cost product commitments to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & Gene™. All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing. For more information about the G-Rex® Grant Program, please contact info@ For more information about LEAN Cell & Gene™, please use this link to register for the free event series. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Sidra Medicine Innovating Care. Transforming Lives From the heart of Qatar, Sidra Medicine, is a private, not-for-profit academic healthcare and research institution for women, children, and young people. Established by the Qatar Foundation for Education, Science, and Community Development, Sidra Medicine is committed to delivering exceptional patient and family-focused care, conducting innovative biomedical and clinical research, and providing a personalized journey of care and cure and precision medicine specifically for rare and genetic diseases. To access our specialised healthcare or international patient services, including pediatric care, women's health, and rare disease treatment or to book a consultation at one of our private clinics, please call +974 40033333 or visit our website at For more information, follow us on Facebook, Instagram, X and LinkedIn. View original content to download multimedia: SOURCE Bio-Techne Corporation
